Comparative Pharmacology
Head-to-head clinical analysis: LOTRIMIN AF versus MENTAX TC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRIMIN AF versus MENTAX TC.
LOTRIMIN AF vs MENTAX-TC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
MENTAX-TC (butenafine hydrochloride) is a benzylamine antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and disruption of membrane integrity, resulting in fungal cell death.
Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.
Apply a thin layer to affected area once daily for 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life of absorbed clotrimazole is approximately 3.5–4 hours, but this is clinically irrelevant due to negligible systemic absorption after topical application.
Terminal elimination half-life is approximately 20 hours (range 16-24 hours), allowing once-daily dosing.
Less than 1% of topical clotrimazole is absorbed; absorbed drug is metabolized in the liver to inactive metabolites and excreted primarily in feces (approximately 69%) and urine (approximately 21%) via biliary and renal routes.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine, ~60% in feces as metabolites, <1% in bile as unchanged drug.
Category C
Category C
Topical Antifungal
Topical Antifungal